Secretion of functionally active complement factor H related protein 5 (FHR5) by primary tumour cells derived from Glioblastoma Multiforme patients

Brandstatter, 2012, Purification and biochemical characterization of functional complement factor H from human plasma fractions, Vox Sang., 103, 201, 10.1111/j.1423-0410.2012.01610.x Chang, 2016, CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory t cells and myeloid-derived suppressor cells, Cancer Res., 76, 5671, 10.1158/0008-5472.CAN-16-0144 Clark, 2015, Role of factor H and related proteins in regulating complement activation in the Macula, and relevance to age-related macular degeneration, J. Clin. Med., 4, 18, 10.3390/jcm4010018 Csincsi, 2015, Factor H-related protein 5 interacts with pentraxin 3 and the extracellular matrix and modulates complement activation, J. Immunol., 194, 4963, 10.4049/jimmunol.1403121 Davies, 1989, CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells, J. Exp. Med., 170, 637, 10.1084/jem.170.3.637 Faithfull, 2005, Palliative care of patients with a primary malignant brain tumour: case review of service use and support provided, Palliat. Med., 19, 545, 10.1191/0269216305pm1068oa Fearon, 1977, Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins, J. Exp. Med., 146, 22, 10.1084/jem.146.1.22 Fearon, 1979, Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane, Proc. Natl. Acad. Sci. U.S.A., 76, 5867, 10.1073/pnas.76.11.5867 Fujisawa, 1999, Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter, Am. J. Pathol., 155, 387, 10.1016/S0002-9440(10)65135-8 Furnari, 2007, Malignant astrocytic glioma: genetics, biology, and paths to treatment, Genes Dev., 21, 2683, 10.1101/gad.1596707 Gabrusiewicz, 2014, Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes, Oncotarget, 5, 2208, 10.18632/oncotarget.1893 Gasque, 1992, Expression of complement components of the alternative pathway by glioma cell lines, J. Immunol., 149, 1381, 10.4049/jimmunol.149.4.1381 Goicoechea de Jorge, 2013, Dimerization of complement factor H-related proteins modulates complement activation in vivo, Proc. Natl. Acad. Sci. U.S.A., 110, 4685, 10.1073/pnas.1219260110 Gordon, 1995, ’Identification of complement regulatory domains in human factor H, J. Immunol., 155, 348, 10.4049/jimmunol.155.1.348 Gorter, 1999, Immune evasion of tumor cells using membrane-bound complement regulatory proteins, Immunol. Today, 20, 576, 10.1016/S0167-5699(99)01537-6 Hermanson, 1992, Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops, Cancer Res., 52, 3213 Iglesia, 2016, Genomic analysis of immune cell infiltrates across 11 tumor types, J. Natl. Cancer Inst., 108, 10.1093/jnci/djw144 Jokiranta, 2000, Each of the three binding sites on complement factor H interacts with a distinct site on C3b, J. Biol. Chem., 275, 27657, 10.1074/jbc.M002903200 Jokiranta, 2005, ’Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site, Am. J. Pathol., 167, 1173, 10.1016/S0002-9440(10)61205-9 Junnikkala, 2000, ’Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1, J. Immunol., 164, 6075, 10.4049/jimmunol.164.11.6075 Jurianz, 1999, Complement resistance of tumor cells: basal and induced mechanisms, Mol. Immunol., 36, 929, 10.1016/S0161-5890(99)00115-7 Kohl, 2006, Self, non-self, and danger: a complementary view, Adv. Exp. Med. Biol., 586, 71, 10.1007/0-387-34134-X_6 Kuhn, 1996, Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H, Eur. J. Immunol., 26, 2383, 10.1002/eji.1830261017 Laemmli, 1970, Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature, 227, 680, 10.1038/227680a0 Liu, 2012, Identifying dysregulated pathways in cancers from pathway interaction networks, BMC Bioinformatics, 13, 11 Maher, 2006, Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities, Cancer Res., 66, 11502, 10.1158/0008-5472.CAN-06-2072 McRae, 2001, Human factor H-related protein 5 (FHR-5). A new complement-associated protein, J. Biol. Chem., 276, 6747, 10.1074/jbc.M007495200 McRae, 2005, Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein, J. Immunol., 174, 6250, 10.4049/jimmunol.174.10.6250 Medjeral-Thomas, 2016, The complement factor H-related proteins, Immunol. Rev., 274, 191, 10.1111/imr.12477 Meri, 1990, Human protectin (CD59), an 18-20-kD homologous complement restriction factor, does not restrict perforin-mediated lysis, J. Exp. Med., 172, 367, 10.1084/jem.172.1.367 Mieczkowski, 2015, Down-regulation of IKKbeta expression in glioma-infiltrating microglia/macrophages is associated with defective inflammatory/immune gene responses in glioblastoma, Oncotarget, 6, 33077, 10.18632/oncotarget.5310 Morgan, 1994, Membrane proteins that protect against complement lysis, Springer Semin. Immunopathol., 15, 369, 10.1007/BF01837366 Oberndorfer, 2008, The end-of-life hospital setting in patients with glioblastoma, J. Palliat. Med., 11, 26, 10.1089/jpm.2007.0137 Ohgaki, 2004, Genetic pathways to glioblastoma: a population-based study, Cancer Res., 64, 6892, 10.1158/0008-5472.CAN-04-1337 Pace, 2009, End of life issues in brain tumor patients, J. Neurooncol., 91, 39, 10.1007/s11060-008-9670-x Ripoche, 1988, ’The complete amino acid sequence of human complement factor H, Biochem. J., 249, 593, 10.1042/bj2490593 Seya, 1986, Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b, J. Exp. Med., 163, 837, 10.1084/jem.163.4.837 Sharma, 1996, Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis, Proc. Natl. Acad. Sci. U.S.A., 93, 10996, 10.1073/pnas.93.20.10996 Skerka, 2013, Complement factor H related proteins (CFHRs), Mol. Immunol., 56, 170, 10.1016/j.molimm.2013.06.001 Soames, 1997, Interaction between human complement components Factor H, factor I and C3b, Biochem. J., 326, 553, 10.1042/bj3260553 Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N. Engl. J. Med., 352, 987, 10.1056/NEJMoa043330 Sugita, 1988, Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels, J. Biochem., 104, 633, 10.1093/oxfordjournals.jbchem.a122524 Weiler, 1976, Control of the amplification convertase of complement by the plasma protein beta1H, Proc. Natl. Acad. Sci. U.S.A., 73, 3268, 10.1073/pnas.73.9.3268 Whaley, 1976, Modulation of the alternative complement pathways by beta 1 H globulin, J. Exp. Med., 144, 1147, 10.1084/jem.144.5.1147 Yu, 2014, Purification, quantification, and functional analysis of Complement Factor H, Methods Mol. Biol., 1100, 207, 10.1007/978-1-62703-724-2_17